AcroMeta Group Limited (SGX: 43F), a Singapore-based facility management services provider, has announced a strategic move into the emerging field of ambient temperature cellular logistics. The company has entered into a non-binding term sheet with Macro HRD SG Pte. Ltd., a Singapore-based healthcare consultancy, to acquire a strategic stake in Macro-ATCLS Pte. Ltd., the entity commercializing Macro's Ambient Temperature Cellular Logistics (ATCLS) technology. Additionally, AcroMeta will have an option to acquire an exclusive licence to deploy this technology across Southeast Asia.
This partnership marks AcroMeta's entry into a sector poised for significant growth. According to Macro's management, the global cell-and-gene-therapy third-party logistics (3PL) market is estimated at US$1.81 billion in 2025 and projected to reach US$16.95 billion by 2035, representing a compound annual growth rate of 25.1%. The broader markets cited include immune-cell therapy (US$5.2 billion) and organ transplantation (US$47 billion). ATCLS estimates a serviceable addressable market of approximately US$14.5 billion by 2032.
The ATCLS technology is designed to transform the transportation of living cells and temperature-sensitive biological materials by eliminating reliance on conventional refrigerated or cryogenic cold chains. It uses proprietary ambient-temperature preservation and reactivation technologies, supported by a Gradient Equilibrium Decision Modeling (GEDM) platform for real-time governance, chain-of-identity, and process control. This allows dormant living cells to be transported at ambient temperature and reactivated at the point of use, potentially reducing costs and overcoming geographic limitations of traditional cold-chain logistics.
For AcroMeta, this partnership aligns with its strategy to diversify beyond core operations. Executive Director Lawrence Toh stated, "This proposed strategic partnership gives us the opportunity to build a position in an industry where cell and gene therapy logistics are expected to grow at double-digit rates in the years ahead." The exclusive licensing arrangement for Southeast Asia, including the right to appoint sub-licensees, would provide AcroMeta with significant commercial reach and a first right to acquire additional territories.
The move comes as AcroMeta continues to evaluate strategic opportunities to support long-term value creation for shareholders. The Board remains focused on disciplined capital allocation as the Group progresses through its next phase of development.
Macro HRD SG Pte. Ltd., established in 2024, is a biotechnology and therapeutics company focusing on scalable precision-medicine solutions for high-burden infectious diseases. Its portfolio includes innovative approaches for HIV/AIDS, HPV, and other enveloped viruses. The ATCLS technology is licensed by Macro HRD and is being commercialized through Macro-ATCLS.
This strategic partnership positions AcroMeta to capitalize on the rapidly expanding fields of stem cells, CAR-T/immune-cell therapy, gene therapy, regenerative medicine, and organ transplantation. By securing exclusive rights in Southeast Asia, AcroMeta aims to become a key player in bringing this innovative technology to the region, potentially reshaping how temperature-sensitive biological materials are transported.
